Table 3.

Regimens and characteristics of antirash agents.

Class	Drug and Recommended Dosage	Other Considerations for Treatment
Sunscreen	•Broad-spectrum mineral sunscreen, SPF 15 or higher; apply to face and other exposed areas [66]	•SPF/UVA-PF should depend on patient's phototype and induced photosensitivity [66]
Nonsedating antihistamines	•Cetirizine 10 mg OD (prophylaxis); 10 mg BID (grade ≥1 rash) •Loratadine 10 mg OD (prophylaxis); 10 mg BID (grade ≥1 rash) •Fexofenadine 180 mg OD (prophylaxis); 180 mg BID (grade ≥1 rash)	•Risk of urinary retention, vasodilation, constipation, blurred vision, dry eyes, reduced motor skills [67]
Sedating antihistamines	•Diphenhydramine 25–50 mg at bedtime •Hydroxyzine 25 mg at bedtime	•Risk of CNS depression, photosensitization, urinary retention [67] •Contraindicated in patients with acute asthma exacerbation, narrow-angle glaucoma, GI obstruction, and BPH [67]
Topical corticosteroids	•Triamcinolone 0.1% cream or lotion BID •Fluocinonide 0.05% cream or lotion BID	•Risk for skin atrophy, striae, rosacea, perioral dermatitis, acne, purpura with long-term use (>12 weeks) [68] •Less common reactions include hypertrichosis, change in skin pigmentation, delayed wound healing, exacerbation of skin infections [68] •May rarely lead to hyperglycemia, glaucoma, and adrenal insufficiency [68]
Oral corticosteroids	•Prednisone 0.5–1 mg/kg/daily or equivalent	•Risk of hyperglycemia, immunosuppression, osteoporosis/fractures, weight gain, CVD, dyslipidemia, myopathy, cataracts, glaucoma, psychiatric disturbances, HPA-axis suppression [69]
GABA agonist	•Gabapentin 300 mg TID •Pregabalin 50 mg BID	•Risk of somnolence, dizziness, peripheral edema (gabapentin)

BID, twice daily; BPH, benign prostatic hypertrophy; CNS, central nervous system; CVD, cardiovascular disease; GABA, gamma-aminobutyric acid; HPA, hypothalamic-pituitary-adrenal; GI, gastrointestinal; OD, once daily; SPF, sun protection factor; TID, thrice daily; UVA-PF, ultraviolet A protection factor.